NCT04636814: An ongoing trial by Chiesi Farmaceutici S.p.A.
This trial is ongoing. It must report results 6 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04636814 |
|---|---|
| Title | A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 12, 2021 |
| Completion date | Dec. 23, 2025 |
| Required reporting date | Dec. 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 29, 2026 |
| Days late | None |